Compare Danaos Corporation (DAC) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaos Corporation vs Sana Biotechnology Inc — how do they compare? Danaos Corporation trades at $128.26 (market cap $2.36B), while Sana Biotechnology Inc trades at $3.48 (market cap $994.89M). The key difference: Danaos Corporation is far larger — about 2.4× Sana Biotechnology Inc's market cap, and Danaos Corporation pays a 2.78% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| DAC | SANA | |
|---|---|---|
Market Cap | $2.36B | $994.89M |
Sector | Technology | Health |
52-Week High | $134.63 | $5.92 |
52-Week Low | $84.05 | $2.68 |
Enterprise Value | $2.36B | $969.08M |
Dividend Yield | 2.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaos Corporation (DAC) trades at $129.35, up 0.75% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 4.57, P/B of 0.6, and net income margin of 49.85% (2026 trend). Recent Q1 2026 earnings beat expectations, and the company maintains a consistent dividend policy. Analyst sentiment is mixed with a 40% buy rating. The stock is near resistance at $130, with RSI_6 indicating potential overbought conditions.
The outlook for DAC remains positive due to attractive valuation, high profitability, and a robust containership backlog. Key risks include exposure to shipping rate volatility and capital allocation decisions. Upside potential is supported by earnings momentum and dividend yield, but investors should monitor industry cyclicality and execution on fleet expansion.
SANA Biotechnology trades at $3.64, down 5.45% over 24 hours, with a bullish technical signal and strong analyst support (81.82% buy ratings). Recent news highlights clinical progress, including NEJM publications and conference presentations, but financials show significant losses with a net income of -$244.17M in 2025 and negative cash flows.
The outlook is mixed: strong scientific momentum and Wall Street optimism contrast with deep financial losses and high burn rate. Key risks include funding needs and clinical trial outcomes, while potential upside hinges on successful product development and partnerships.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaos Corporation
Danaos is a leading international owner of containerships, providing seaborne transportation services globally. It charters its fleet of vessels to major shipping lines across Asia, Europe, and the Americas.
Read more on DAC →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
